Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-009128Source: DataRank Database

Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors is a research paper published in Journal for ImmunoTherapy of Cancer (2024). On theSindex it has a DataRank of 0.380. It has been cited 9 times, with 6 citing works in its 1-hop citation network.

N/A

0.380DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access9 citations · 6 citing works in its network

Download PDF

Cite:

Linked data & code

nct doi

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT02834013

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (8 grants)Impact (FWCI 2.86)OA: goldTopics (67)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 91%Citation Network 9%

Base Score Contribution

0.345

From this paper's citation signal

Citation Network Contribution

0.0347

From 2 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 6 citers.

Case Report: Nirogacestat therapy induces rapid response in a patient with refractory, life-threatening desmoid tumor
Frontiers in Oncology20252 citations30 referencesContributes 0.037
Oncogenic mutation-driven metabolism-immunity regulatory axis: Potential prospects for thyroid cancer precision therapy
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer20252 citations261 referencesContributes 0.004
Clinical and morphological features of desmoid-type fibromatosis
Yakut Medical Journal20250 citations33 referencesContributes 0.000
Management of Desmoid Tumors
Advances in Oncology20260 citations44 referencesContributes 0.000
Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma
Gynecologic Oncology20260 citations17 referencesContributes 0.000

Authors (16)

Megan Othus ORCID,Sandip Pravin Patel ORCID,Benjamin Powers ORCID,Chung-Tsen Hsueh ORCID,Rangaswamy Govindarajan

Live enrichment

PubMed:39343510 PMC:PMC11440191 OpenAlex:https://openalex.org/W4402951338

NIH/NCI/NCTN

Grant: U10CA180819

NIH/NCI/NCTN

Grant: U10CA180820

NIH/NCI/NCTN

Grant: U10CA180888

Bristol Myers Squibb Company

Grant: N/A

National Institutes of Health

Grant: 3U10CA180820-02S3

ECOG-ACRIN Operations Center

National Institutes of Health

Grant: 2U10CA180819-06

SWOG Statistics and Data Management Center

National Institutes of Health

Grant: 3U10CA180888-03S1

SWOG Network Group Operations Center of the NCTN

National Institutes of Health

Grant: 5UG1CA233198-05

MCW NCTN Lead Academic Participating Site

FWCI

2.86

Citation Percentile

0.9%

Citation Trend

2025

2026

goldLicense: cc-by-nc

journalhttps://jitc.bmj.com/content/12/9/e009128.full.pdf

GOLDhttps://doi.org/10.1136/jitc-2024-009128

publisherhttps://jitc.bmj.com/content/12/9/e009128.full.pdf

publisherhttps://syndication.highwire.org/content/doi/10.1136/jitc-2024-009128

repositoryhttps://pubmed.ncbi.nlm.nih.gov/39343510

Fields of Study

Soft tissue tumor case studiesSoft tissue tumors and treatmentSarcoma Diagnosis and TreatmentMedicine03 medical and health sciences0302 clinical medicineHumansMaleFemaleMiddle AgedAdultCTLA-4 AntigenDesmoid TumorsAgedYoung AdultProspective StudiesIpilimumabImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorNivolumabAdolescent

MeSH Terms

IpilimumabNivolumabImmune Checkpoint InhibitorsAdolescentAdultAgedFemaleHumansMaleMiddle AgedProspective StudiesFibromatosis, AggressiveDesmoid TumorsYoung AdultCTLA-4 AntigenProgrammed Cell Death 1 Receptor

Keywords

MedicineIpilimumabNivolumabResponse Evaluation Criteria in Solid TumorsInternal medicineClinical endpointOncologyClinical trialSurgeryPhases of clinical researchGastroenterologyImmunotherapyCancerCombination therapyImmune Checkpoint InhibitorMaleAdultDesmoid TumorsAdolescentProgrammed Cell Death 1 ReceptorNeoplasms. Tumors. Oncology. Including cancer and carcinogensMiddle AgedYoung AdultHumansFemaleCTLA-4 AntigenProspective StudiesImmune Checkpoint InhibitorsRC254-282Aged

Sustainable Development Goals

SDG 0: Good health and well-being